Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Exploratory study of NS 065/NCNP 01 in Duchenne muscular dystrophy

Trial Profile

Exploratory study of NS 065/NCNP 01 in Duchenne muscular dystrophy

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 09 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Viltolarsen (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Adverse reactions; First in man
  • Sponsors Nippon Shinyaku
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 19 Apr 2018 According to a Nippon Shinyaku media release, registry of Muscular Dystrophy (Remudy) was utilized for patient recruitment in The Study.
    • 19 Apr 2018 Results published in the Nippon Shinyaku Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top